Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations, Chief Executive Officer Mark Velleca said during a Jefferies fireside chat following the company’s presentations at ASCO.
Velleca described Black Diamond as a “precision small molecule oncology company” and said silevertinib is being evaluated as a potential “first and best-in-class fourth generation EGFR inhibitor.” The drug is in Phase 2 testing for patients with non-small cell lung cancer and glioblastoma.
